Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lexicon Pharmaceuticals has submitted an investigational new drug application with the FDA to start an ascending single-dose Phase I trial for an oral drug candidate for rheumatoid arthritis and other autoimmune conditions.
Subscribe to our email newsletter
This initial trial is designed to evaluate the safety, tolerability, and pharmacokinetics of LX2931. Lexicon expects to initiate clinical trials with LX2931 following FDA review.
Philip Brown, vice president of clinical development at Lexicon, said: “As an orally-delivered modulator of lymphocyte activity, we believe LX2931 has potential to be an important new therapy for rheumatoid arthritis and other autoimmune disorders. We can now add immunology to the list of therapeutic areas with clinical-stage compounds from Lexicon’s drug discovery pipeline.”